Laguens R P, Colmerauer M E, Segal A, Pasqualini C D
Int J Cancer. 1978 Jun 15;21(6):779-83. doi: 10.1002/ijc.2910210616.
In an experimental model conditioning for enhancement, an AKR lymphoma was made to grow in BALB/c mice, permitting the simultaneous comparison of tumor-bearing (progressor) and tumor-rejecting (regressor) animals. By immunofluorescence using as target AKR lymphoma and normal thymus cells, both acetone-fixed and unfixed, it was observed that the allogeneic progressor serum contained three antibodies, two of which could be asborbed by thymocytes while the other combined selectively with the acetone-fixed lymphoma target. This tumor-specific antibody could not be detected in regressor serum which, on the other hand, could be completely absorbed by thymocytes. The identification of this acetone-resistant tumor antigen led to the preparation of aceton-treated acellular lymphoma extracts: a precipitate was obtained which upon inoculation in BALB/c mice produced an antiserum that combined selectively with lymphoma targets. In vivo experiments showed that pretreatment with this antigen led to a significant increase in allogeneic tumor incidence, 76% as compared to 37% in the controls. It is concluded that in this allogeneic model, an acetone-resistant tumor-specific antigen and the corresponding antibody are involved in tumor enhancement.
在一种用于增强作用的实验模型中，使AKR淋巴瘤在BALB/c小鼠体内生长，从而能够同时比较荷瘤（进展型）和肿瘤排斥（消退型）动物。通过免疫荧光法，以AKR淋巴瘤和正常胸腺细胞为靶标，包括丙酮固定和未固定的细胞，观察到同种异体进展型动物血清含有三种抗体，其中两种可被胸腺细胞吸收，而另一种则选择性地与丙酮固定的淋巴瘤靶标结合。在消退型动物血清中未检测到这种肿瘤特异性抗体，而消退型动物血清可被胸腺细胞完全吸收。对这种丙酮抗性肿瘤抗原的鉴定促使制备了经丙酮处理的无细胞淋巴瘤提取物：获得一种沉淀物，将其接种到BALB/c小鼠体内可产生一种能选择性地与淋巴瘤靶标结合的抗血清。体内实验表明，用这种抗原进行预处理可使同种异体肿瘤发生率显著增加，与对照组的37%相比，达到了76%。由此得出结论，在这种同种异体模型中，一种丙酮抗性肿瘤特异性抗原和相应抗体参与了肿瘤增强作用。
